← Browse by Condition
Medical Condition
portal hypertension
Total Trials
9
Recruiting Now
9
Trial Phases
Phase 4
Hypertension remains the most common treatable cardiovascular risk factor globally, yet blood pressure control rates remain suboptimal despite multiple effective drug classes. Clinical trials now investigate novel mechanisms including aldosterone synthase inhibitors, renal denervation devices, and RNA-based therapies targeting angiotensinogen to achieve durable pressure reduction with minimal pill burden.
Active research includes zilebesiran (RNA interference targeting angiotensinogen), baxdrostat (aldosterone synthase inhibitor), ultrasound renal denervation (Symplicity HTN-4), and resistant hypertension approaches combining SGLT2 inhibitors with MRA spironolactone. Ambulatory blood pressure monitoring is increasingly used as the primary endpoint instead of clinic readings.
Frequently Asked Questions — portal hypertension Clinical Trials
How many clinical trials are currently recruiting for portal hypertension?
ClinicalMetric currently tracks 9 actively recruiting clinical trials for portal hypertension, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 9. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for portal hypertension?
portal hypertension research spans Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a portal hypertension clinical trial?
Eligibility criteria for portal hypertension trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 4 1
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT04578301
Recruiting
Enrollment
200 pts
Location
Germany
Sponsor
University Hospital, Bonn
NCT06449339 Phase 4
Recruiting
Enrollment
474 pts
Location
Hong Kong
Sponsor
Chinese University of Hong Kon...
NCT06316869
Recruiting
Enrollment
216 pts
Location
China
Sponsor
First Affiliated Hospital of W...
NCT07163689
Recruiting
Enrollment
360 pts
Location
France
Sponsor
Centre Hospitalier Universitai...
NCT07304466
Recruiting
Enrollment
50 pts
Location
Turkey (Türkiye)
Sponsor
Istanbul Medipol University Ho...
NCT07439939
Recruiting
Enrollment
45 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
NCT06266260
Recruiting
Enrollment
50 pts
Location
Italy
Sponsor
Fondazione Policlinico Univers...
NCT06863012
Recruiting
Enrollment
20 pts
Location
Spain
Sponsor
Fundacio Privada Mon Clinic Ba...
NCT06970509
Recruiting
Enrollment
1,450 pts
Location
China
Sponsor
Shanghai Zhongshan Hospital
Related Conditions
liver cirrhosis (2) cirrhosis (2) esophageal varices (2) surgery (1) acute on chronic liver failure (1) non cirrhotic portal hypertension (1) hepatic decompensation (1) advanced chronic liver disease (1) tips (1) porto sinusoidal vascular disease (1) refractory ascite (1) gastrointestinal hemorrhage (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology